Motilal Oswal Wealth Management has highlighted Bajaj Finance and Molbio Diagnostics as key growth stocks for the week starting October 12, 2026. Bajaj Finance is moving forward with a Rs 17,500 crore capital raise, while Molbio is expanding its diagnostic technology platform. Investors are balancing these growth initiatives against risks like market competition and the high valuations often seen in the healthcare technology sector.
Motilal Oswal Wealth Management has identified Bajaj Finance and Molbio Diagnostics as significant entities to watch as of October 12, 2026. The brokerage report focuses on the growth strategies these companies are currently employing to expand their market presence. For investors, understanding these moves involves looking past the headlines to see how the capital deployment and technology adoption may affect future financial performance.
Bajaj Finance has announced a major capital infusion plan, receiving approval to raise Rs 17,500 crore. This includes Rs 11,700 crore through a Qualified Institutional Placement and Rs 5,800 crore via preferential warrants. The company intends to use these funds to strengthen its capital base, which is necessary to support its growing loan book in a competitive lending environment. The lender recently reported a 26.5% year-on-year increase in Assets Under Management, reaching Rs 5.85 lakh crore. While this highlights strong demand, investors often watch such large capital raises for potential dilution, which can affect earnings per share in the short term. Additionally, the non-banking financial sector faces ongoing challenges from shifting regulatory norms and intense competition, which may pressure profit margins over time.
Molbio Diagnostics is being watched for its aggressive expansion in the healthcare technology space. The company’s primary focus is its proprietary Truenat platform, which provides molecular testing results with a 60-minute turnaround. With over 12,500 devices installed across 90 countries, the firm is working to move beyond its historical dependence on tuberculosis testing. The company is also moving into digital pathology through recent acquisitions like Prognosys and OptraSCAN, aiming to integrate advanced imaging into its offerings. Analysts have projected a 23% revenue compound annual growth rate through fiscal 2029, though this growth expectation carries its own set of challenges.
The healthcare diagnostics sector is capital-intensive, and Molbio faces elevated working capital requirements as it scales its operations globally. Furthermore, the company currently trades at a premium valuation, which implies that the market expects consistent, high-speed earnings growth. If the company fails to execute its digital pathology expansion or faces delays in the adoption of its new assays, this valuation may become difficult to sustain. Reliance on government-led diagnostic programs also creates a layer of dependency that investors should monitor.
Moving forward, shareholders of Bajaj Finance will likely track the actual timeline and pricing of the capital raise, along with how the new funds are deployed to sustain loan growth without sacrificing asset quality. For Molbio Diagnostics, the key monitorable will be the actual revenue conversion from its new digital pathology business and its ability to manage working capital needs effectively while maintaining its global device installation pace.